HAE — Haemonetics Corporation
$122.94
+$0.23 (+0.19%)
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments.
Market Cap
$5.60B
Forward P/E
19.8x
52-Week Range
N/A
HAE Price History
Revenue vs. Net Income
$1.3B
Revenue · FY2026
Annual. Net margin is shown under each year.
Free Cash Flow
$260M
FCF · FY2026
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
7.4%
ROCE · FY2026
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
1.5x
Assets ÷ liabilities · FY2026
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
2.5%
CapEx · FY2026
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
-6.7%
Net buyback · FY2026
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
